Eurofins-Cerep SA (ALECR) - Total Assets
Based on the latest financial reports, Eurofins-Cerep SA (ALECR) holds total assets worth €89.02 Million EUR (≈ $104.07 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Eurofins-Cerep SA cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Eurofins-Cerep SA - Total Assets Trend (2000–2025)
This chart illustrates how Eurofins-Cerep SA's total assets have evolved over time, based on quarterly financial data. See Eurofins-Cerep SA (ALECR) net assets for net asset value and shareholders' equity analysis.
Eurofins-Cerep SA - Asset Composition Analysis
Current Asset Composition (December 2025)
Eurofins-Cerep SA's total assets of €89.02 Million consist of 89.2% current assets and 10.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 10.3% |
| Accounts Receivable | €8.09 Million | 9.1% |
| Inventory | €2.54 Million | 2.9% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €77.35K | 0.1% |
| Goodwill | €2.23 Million | 2.5% |
Asset Composition Trend (2000–2025)
This chart illustrates how Eurofins-Cerep SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Eurofins-Cerep SA market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eurofins-Cerep SA's current assets represent 89.2% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 10.3% of total assets in 2025, up from 8.1% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 9.1% of total assets.
Eurofins-Cerep SA Competitors by Total Assets
Key competitors of Eurofins-Cerep SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Shanghai Labway Clinical Laboratory Co Ltd
SHE:301060
|
China | CN¥2.35 Billion |
|
Ningbo MedicalSystem Biotechnology Co Ltd
SHE:300439
|
China | CN¥3.66 Billion |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
|
INIFY LABORATORIES AB
F:WY60
|
Germany | €204.64 Million |
|
Check Cap Ltd
NASDAQ:CHEK
|
USA | $377.00K |
Eurofins-Cerep SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.83 | 6.94 | 4.47 |
| Quick Ratio | 7.58 | 6.62 | 4.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €69.27 Million | €62.18 Million | €29.19 Million |
Eurofins-Cerep SA - Advanced Valuation Insights
This section examines the relationship between Eurofins-Cerep SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.14 |
| Latest Market Cap to Assets Ratio | 0.98 |
| Asset Growth Rate (YoY) | 5.9% |
| Total Assets | €89.02 Million |
| Market Capitalization | $87.26 Million USD |
Valuation Analysis
Near Book Valuation: The market values Eurofins-Cerep SA's assets close to their book value (0.98x), suggesting investors view the company's assets at approximately fair value.
Positive Asset Growth: Eurofins-Cerep SA's assets grew by 5.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Eurofins-Cerep SA (2000–2025)
The table below shows the annual total assets of Eurofins-Cerep SA from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €89.02 Million ≈ $104.07 Million |
+5.90% |
| 2024-12-31 | €84.06 Million ≈ $98.28 Million |
+6.07% |
| 2023-12-31 | €79.25 Million ≈ $92.65 Million |
+11.54% |
| 2022-12-31 | €71.05 Million ≈ $83.06 Million |
+18.95% |
| 2021-12-31 | €59.73 Million ≈ $69.83 Million |
+29.67% |
| 2020-12-31 | €46.06 Million ≈ $53.85 Million |
+15.30% |
| 2019-12-31 | €39.95 Million ≈ $46.71 Million |
+13.31% |
| 2018-12-31 | €35.26 Million ≈ $41.22 Million |
+16.83% |
| 2017-12-31 | €30.18 Million ≈ $35.28 Million |
+16.33% |
| 2016-12-31 | €25.94 Million ≈ $30.33 Million |
+3.02% |
| 2015-12-31 | €25.18 Million ≈ $29.44 Million |
+9.97% |
| 2014-12-31 | €22.90 Million ≈ $26.77 Million |
-17.89% |
| 2013-12-31 | €27.89 Million ≈ $32.60 Million |
-7.92% |
| 2012-12-31 | €30.28 Million ≈ $35.40 Million |
-7.45% |
| 2011-12-31 | €32.72 Million ≈ $38.26 Million |
-8.84% |
| 2010-12-31 | €35.90 Million ≈ $41.97 Million |
-18.98% |
| 2009-12-31 | €44.31 Million ≈ $51.80 Million |
-19.30% |
| 2008-12-31 | €54.91 Million ≈ $64.19 Million |
-12.47% |
| 2007-12-31 | €62.73 Million ≈ $73.34 Million |
-17.86% |
| 2006-12-31 | €76.37 Million ≈ $89.29 Million |
-8.70% |
| 2005-12-31 | €83.65 Million ≈ $97.79 Million |
+30.95% |
| 2004-12-31 | €63.87 Million ≈ $74.68 Million |
+24.65% |
| 2003-12-31 | €51.24 Million ≈ $59.91 Million |
+7.39% |
| 2002-12-31 | €47.72 Million ≈ $55.78 Million |
+16.67% |
| 2001-12-31 | €40.90 Million ≈ $47.81 Million |
+72.80% |
| 2000-12-31 | €23.67 Million ≈ $27.67 Million |
-- |
About Eurofins-Cerep SA
Eurofins-Cerep SA provides various drug discovery services to pharmaceutical, biopharmaceutical, and biotechnology companies France and internationally. The company's research services include compound management, and high-throughput screening and profiling. The company was formerly known as Cerep SA and changed its name to Eurofins-Cerep SA in June 2014. Eurofins-Cerep SA was founded in 1989 and… Read more